PMC:7534795 / 63272-63964 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T252","span":{"begin":145,"end":151},"obj":"Body_part"},{"id":"T253","span":{"begin":445,"end":452},"obj":"Body_part"},{"id":"T254","span":{"begin":458,"end":469},"obj":"Body_part"},{"id":"T255","span":{"begin":478,"end":495},"obj":"Body_part"},{"id":"T256","span":{"begin":492,"end":495},"obj":"Body_part"},{"id":"T257","span":{"begin":520,"end":530},"obj":"Body_part"}],"attributes":[{"id":"A252","pred":"fma_id","subj":"T252","obj":"http://purl.org/sig/ont/fma/fma9637"},{"id":"A253","pred":"fma_id","subj":"T253","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A254","pred":"fma_id","subj":"T254","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A255","pred":"fma_id","subj":"T255","obj":"http://purl.org/sig/ont/fma/fma67199"},{"id":"A256","pred":"fma_id","subj":"T256","obj":"http://purl.org/sig/ont/fma/fma74412"},{"id":"A257","pred":"fma_id","subj":"T257","obj":"http://purl.org/sig/ont/fma/fma82738"}],"text":"inflammatory and the cardioprotective ACE2/Ang (1–7) effectors. (E) N-3 PUFAs enhance antioxidant capacity and attenuate oxidative stress in the tissue. (F) N-3 PUFAs ameliorate coagulopathy by exerting anti-thrombotic effects. (G) The triglyceride-lowering effect of n-3 PUFAs may play a key role in blunting the exaggerated inflammation observed in patients with COVID-19. ACE, Angiotensin-converting enzyme; Ang, Angiotensin; CRP, C-reactive protein; IL, Interleukin; mtDNA, Mitochondrial DNA; PUFA, Poly unsaturated fatty acid; ROS, Reactive oxygen species; TGs, Triglycerides; TNF-α, Tumor necrosis factor alpha; TX, Thromboxane.\n\n8.1 The anti-inflammatory properties of n-3 PUFAs\nAs me"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T90","span":{"begin":145,"end":151},"obj":"Body_part"}],"attributes":[{"id":"A90","pred":"uberon_id","subj":"T90","obj":"http://purl.obolibrary.org/obo/UBERON_0000479"}],"text":"inflammatory and the cardioprotective ACE2/Ang (1–7) effectors. (E) N-3 PUFAs enhance antioxidant capacity and attenuate oxidative stress in the tissue. (F) N-3 PUFAs ameliorate coagulopathy by exerting anti-thrombotic effects. (G) The triglyceride-lowering effect of n-3 PUFAs may play a key role in blunting the exaggerated inflammation observed in patients with COVID-19. ACE, Angiotensin-converting enzyme; Ang, Angiotensin; CRP, C-reactive protein; IL, Interleukin; mtDNA, Mitochondrial DNA; PUFA, Poly unsaturated fatty acid; ROS, Reactive oxygen species; TGs, Triglycerides; TNF-α, Tumor necrosis factor alpha; TX, Thromboxane.\n\n8.1 The anti-inflammatory properties of n-3 PUFAs\nAs me"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T427","span":{"begin":178,"end":190},"obj":"Disease"},{"id":"T428","span":{"begin":326,"end":338},"obj":"Disease"},{"id":"T429","span":{"begin":365,"end":373},"obj":"Disease"},{"id":"T430","span":{"begin":589,"end":594},"obj":"Disease"}],"attributes":[{"id":"A427","pred":"mondo_id","subj":"T427","obj":"http://purl.obolibrary.org/obo/MONDO_0001531"},{"id":"A428","pred":"mondo_id","subj":"T428","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A429","pred":"mondo_id","subj":"T429","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A430","pred":"mondo_id","subj":"T430","obj":"http://purl.obolibrary.org/obo/MONDO_0005070"}],"text":"inflammatory and the cardioprotective ACE2/Ang (1–7) effectors. (E) N-3 PUFAs enhance antioxidant capacity and attenuate oxidative stress in the tissue. (F) N-3 PUFAs ameliorate coagulopathy by exerting anti-thrombotic effects. (G) The triglyceride-lowering effect of n-3 PUFAs may play a key role in blunting the exaggerated inflammation observed in patients with COVID-19. ACE, Angiotensin-converting enzyme; Ang, Angiotensin; CRP, C-reactive protein; IL, Interleukin; mtDNA, Mitochondrial DNA; PUFA, Poly unsaturated fatty acid; ROS, Reactive oxygen species; TGs, Triglycerides; TNF-α, Tumor necrosis factor alpha; TX, Thromboxane.\n\n8.1 The anti-inflammatory properties of n-3 PUFAs\nAs me"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T378","span":{"begin":64,"end":69},"obj":"http://purl.obolibrary.org/obo/CLO_0037161"},{"id":"T379","span":{"begin":287,"end":288},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T380","span":{"begin":589,"end":616},"obj":"http://purl.obolibrary.org/obo/PR_000000134"}],"text":"inflammatory and the cardioprotective ACE2/Ang (1–7) effectors. (E) N-3 PUFAs enhance antioxidant capacity and attenuate oxidative stress in the tissue. (F) N-3 PUFAs ameliorate coagulopathy by exerting anti-thrombotic effects. (G) The triglyceride-lowering effect of n-3 PUFAs may play a key role in blunting the exaggerated inflammation observed in patients with COVID-19. ACE, Angiotensin-converting enzyme; Ang, Angiotensin; CRP, C-reactive protein; IL, Interleukin; mtDNA, Mitochondrial DNA; PUFA, Poly unsaturated fatty acid; ROS, Reactive oxygen species; TGs, Triglycerides; TNF-α, Tumor necrosis factor alpha; TX, Thromboxane.\n\n8.1 The anti-inflammatory properties of n-3 PUFAs\nAs me"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T32324","span":{"begin":72,"end":77},"obj":"Chemical"},{"id":"T84667","span":{"begin":86,"end":97},"obj":"Chemical"},{"id":"T12453","span":{"begin":161,"end":166},"obj":"Chemical"},{"id":"T24148","span":{"begin":236,"end":248},"obj":"Chemical"},{"id":"T15454","span":{"begin":272,"end":277},"obj":"Chemical"},{"id":"T67393","span":{"begin":380,"end":391},"obj":"Chemical"},{"id":"T14430","span":{"begin":416,"end":427},"obj":"Chemical"},{"id":"T31050","span":{"begin":445,"end":452},"obj":"Chemical"},{"id":"T10144","span":{"begin":454,"end":456},"obj":"Chemical"},{"id":"T4756","span":{"begin":492,"end":495},"obj":"Chemical"},{"id":"T24904","span":{"begin":497,"end":501},"obj":"Chemical"},{"id":"T70192","span":{"begin":508,"end":530},"obj":"Chemical"},{"id":"T55358","span":{"begin":520,"end":530},"obj":"Chemical"},{"id":"T92131","span":{"begin":526,"end":530},"obj":"Chemical"},{"id":"T82150","span":{"begin":532,"end":535},"obj":"Chemical"},{"id":"T62728","span":{"begin":537,"end":560},"obj":"Chemical"},{"id":"T4591","span":{"begin":546,"end":552},"obj":"Chemical"},{"id":"T61931","span":{"begin":611,"end":616},"obj":"Chemical"},{"id":"T3853","span":{"begin":618,"end":620},"obj":"Chemical"},{"id":"T97296","span":{"begin":681,"end":686},"obj":"Chemical"}],"attributes":[{"id":"A36034","pred":"chebi_id","subj":"T32324","obj":"http://purl.obolibrary.org/obo/CHEBI_26208"},{"id":"A45578","pred":"chebi_id","subj":"T84667","obj":"http://purl.obolibrary.org/obo/CHEBI_22586"},{"id":"A49473","pred":"chebi_id","subj":"T12453","obj":"http://purl.obolibrary.org/obo/CHEBI_26208"},{"id":"A64596","pred":"chebi_id","subj":"T24148","obj":"http://purl.obolibrary.org/obo/CHEBI_17855"},{"id":"A38147","pred":"chebi_id","subj":"T15454","obj":"http://purl.obolibrary.org/obo/CHEBI_26208"},{"id":"A40847","pred":"chebi_id","subj":"T67393","obj":"http://purl.obolibrary.org/obo/CHEBI_2719"},{"id":"A32677","pred":"chebi_id","subj":"T14430","obj":"http://purl.obolibrary.org/obo/CHEBI_2719"},{"id":"A79963","pred":"chebi_id","subj":"T31050","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A77472","pred":"chebi_id","subj":"T10144","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A65900","pred":"chebi_id","subj":"T10144","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A64404","pred":"chebi_id","subj":"T4756","obj":"http://purl.obolibrary.org/obo/CHEBI_16991"},{"id":"A20279","pred":"chebi_id","subj":"T24904","obj":"http://purl.obolibrary.org/obo/CHEBI_26208"},{"id":"A56881","pred":"chebi_id","subj":"T24904","obj":"http://purl.obolibrary.org/obo/CHEBI_76567"},{"id":"A22044","pred":"chebi_id","subj":"T70192","obj":"http://purl.obolibrary.org/obo/CHEBI_27208"},{"id":"A93121","pred":"chebi_id","subj":"T55358","obj":"http://purl.obolibrary.org/obo/CHEBI_35366"},{"id":"A25419","pred":"chebi_id","subj":"T92131","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"},{"id":"A48116","pred":"chebi_id","subj":"T82150","obj":"http://purl.obolibrary.org/obo/CHEBI_26523"},{"id":"A10781","pred":"chebi_id","subj":"T62728","obj":"http://purl.obolibrary.org/obo/CHEBI_26523"},{"id":"A44627","pred":"chebi_id","subj":"T4591","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A62703","pred":"chebi_id","subj":"T61931","obj":"http://purl.obolibrary.org/obo/CHEBI_30216"},{"id":"A49192","pred":"chebi_id","subj":"T3853","obj":"http://purl.obolibrary.org/obo/CHEBI_26995"},{"id":"A76877","pred":"chebi_id","subj":"T97296","obj":"http://purl.obolibrary.org/obo/CHEBI_26208"}],"text":"inflammatory and the cardioprotective ACE2/Ang (1–7) effectors. (E) N-3 PUFAs enhance antioxidant capacity and attenuate oxidative stress in the tissue. (F) N-3 PUFAs ameliorate coagulopathy by exerting anti-thrombotic effects. (G) The triglyceride-lowering effect of n-3 PUFAs may play a key role in blunting the exaggerated inflammation observed in patients with COVID-19. ACE, Angiotensin-converting enzyme; Ang, Angiotensin; CRP, C-reactive protein; IL, Interleukin; mtDNA, Mitochondrial DNA; PUFA, Poly unsaturated fatty acid; ROS, Reactive oxygen species; TGs, Triglycerides; TNF-α, Tumor necrosis factor alpha; TX, Thromboxane.\n\n8.1 The anti-inflammatory properties of n-3 PUFAs\nAs me"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T113","span":{"begin":326,"end":338},"obj":"http://purl.obolibrary.org/obo/GO_0006954"},{"id":"T114","span":{"begin":595,"end":603},"obj":"http://purl.obolibrary.org/obo/GO_0070265"},{"id":"T115","span":{"begin":595,"end":603},"obj":"http://purl.obolibrary.org/obo/GO_0019835"},{"id":"T116","span":{"begin":595,"end":603},"obj":"http://purl.obolibrary.org/obo/GO_0008219"},{"id":"T117","span":{"begin":595,"end":603},"obj":"http://purl.obolibrary.org/obo/GO_0001906"}],"text":"inflammatory and the cardioprotective ACE2/Ang (1–7) effectors. (E) N-3 PUFAs enhance antioxidant capacity and attenuate oxidative stress in the tissue. (F) N-3 PUFAs ameliorate coagulopathy by exerting anti-thrombotic effects. (G) The triglyceride-lowering effect of n-3 PUFAs may play a key role in blunting the exaggerated inflammation observed in patients with COVID-19. ACE, Angiotensin-converting enzyme; Ang, Angiotensin; CRP, C-reactive protein; IL, Interleukin; mtDNA, Mitochondrial DNA; PUFA, Poly unsaturated fatty acid; ROS, Reactive oxygen species; TGs, Triglycerides; TNF-α, Tumor necrosis factor alpha; TX, Thromboxane.\n\n8.1 The anti-inflammatory properties of n-3 PUFAs\nAs me"}

{"project":"LitCovid-sentences","denotations":[{"id":"T475","span":{"begin":375,"end":634},"obj":"Sentence"},{"id":"T476","span":{"begin":636,"end":686},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"inflammatory and the cardioprotective ACE2/Ang (1–7) effectors. (E) N-3 PUFAs enhance antioxidant capacity and attenuate oxidative stress in the tissue. (F) N-3 PUFAs ameliorate coagulopathy by exerting anti-thrombotic effects. (G) The triglyceride-lowering effect of n-3 PUFAs may play a key role in blunting the exaggerated inflammation observed in patients with COVID-19. ACE, Angiotensin-converting enzyme; Ang, Angiotensin; CRP, C-reactive protein; IL, Interleukin; mtDNA, Mitochondrial DNA; PUFA, Poly unsaturated fatty acid; ROS, Reactive oxygen species; TGs, Triglycerides; TNF-α, Tumor necrosis factor alpha; TX, Thromboxane.\n\n8.1 The anti-inflammatory properties of n-3 PUFAs\nAs me"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T201","span":{"begin":121,"end":137},"obj":"Phenotype"},{"id":"T202","span":{"begin":178,"end":190},"obj":"Phenotype"},{"id":"T203","span":{"begin":589,"end":594},"obj":"Phenotype"}],"attributes":[{"id":"A201","pred":"hp_id","subj":"T201","obj":"http://purl.obolibrary.org/obo/HP_0025464"},{"id":"A202","pred":"hp_id","subj":"T202","obj":"http://purl.obolibrary.org/obo/HP_0003256"},{"id":"A203","pred":"hp_id","subj":"T203","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"inflammatory and the cardioprotective ACE2/Ang (1–7) effectors. (E) N-3 PUFAs enhance antioxidant capacity and attenuate oxidative stress in the tissue. (F) N-3 PUFAs ameliorate coagulopathy by exerting anti-thrombotic effects. (G) The triglyceride-lowering effect of n-3 PUFAs may play a key role in blunting the exaggerated inflammation observed in patients with COVID-19. ACE, Angiotensin-converting enzyme; Ang, Angiotensin; CRP, C-reactive protein; IL, Interleukin; mtDNA, Mitochondrial DNA; PUFA, Poly unsaturated fatty acid; ROS, Reactive oxygen species; TGs, Triglycerides; TNF-α, Tumor necrosis factor alpha; TX, Thromboxane.\n\n8.1 The anti-inflammatory properties of n-3 PUFAs\nAs me"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1848","span":{"begin":38,"end":42},"obj":"Gene"},{"id":"1849","span":{"begin":375,"end":378},"obj":"Gene"},{"id":"1850","span":{"begin":380,"end":409},"obj":"Gene"},{"id":"1851","span":{"begin":411,"end":414},"obj":"Gene"},{"id":"1852","span":{"begin":429,"end":432},"obj":"Gene"},{"id":"1853","span":{"begin":434,"end":452},"obj":"Gene"},{"id":"1854","span":{"begin":497,"end":501},"obj":"Gene"},{"id":"1855","span":{"begin":582,"end":587},"obj":"Gene"},{"id":"1856","span":{"begin":589,"end":616},"obj":"Gene"},{"id":"1857","span":{"begin":351,"end":359},"obj":"Species"},{"id":"1861","span":{"begin":68,"end":77},"obj":"Chemical"},{"id":"1862","span":{"begin":157,"end":166},"obj":"Chemical"},{"id":"1863","span":{"begin":236,"end":248},"obj":"Chemical"},{"id":"1864","span":{"begin":503,"end":530},"obj":"Chemical"},{"id":"1865","span":{"begin":532,"end":535},"obj":"Chemical"},{"id":"1866","span":{"begin":537,"end":560},"obj":"Chemical"},{"id":"1867","span":{"begin":562,"end":565},"obj":"Chemical"},{"id":"1868","span":{"begin":567,"end":580},"obj":"Chemical"},{"id":"1869","span":{"begin":622,"end":633},"obj":"Chemical"},{"id":"1873","span":{"begin":178,"end":190},"obj":"Disease"},{"id":"1874","span":{"begin":326,"end":338},"obj":"Disease"},{"id":"1875","span":{"begin":365,"end":373},"obj":"Disease"},{"id":"1907","span":{"begin":677,"end":686},"obj":"Chemical"}],"attributes":[{"id":"A1848","pred":"tao:has_database_id","subj":"1848","obj":"Gene:59272"},{"id":"A1849","pred":"tao:has_database_id","subj":"1849","obj":"Gene:1636"},{"id":"A1850","pred":"tao:has_database_id","subj":"1850","obj":"Gene:1636"},{"id":"A1851","pred":"tao:has_database_id","subj":"1851","obj":"Gene:283"},{"id":"A1852","pred":"tao:has_database_id","subj":"1852","obj":"Gene:1401"},{"id":"A1853","pred":"tao:has_database_id","subj":"1853","obj":"Gene:1401"},{"id":"A1854","pred":"tao:has_database_id","subj":"1854","obj":"Gene:9933"},{"id":"A1855","pred":"tao:has_database_id","subj":"1855","obj":"Gene:7124"},{"id":"A1856","pred":"tao:has_database_id","subj":"1856","obj":"Gene:7124"},{"id":"A1857","pred":"tao:has_database_id","subj":"1857","obj":"Tax:9606"},{"id":"A1861","pred":"tao:has_database_id","subj":"1861","obj":"MESH:D015525"},{"id":"A1862","pred":"tao:has_database_id","subj":"1862","obj":"MESH:D015525"},{"id":"A1863","pred":"tao:has_database_id","subj":"1863","obj":"MESH:D014280"},{"id":"A1864","pred":"tao:has_database_id","subj":"1864","obj":"MESH:D005231"},{"id":"A1865","pred":"tao:has_database_id","subj":"1865","obj":"MESH:D017382"},{"id":"A1866","pred":"tao:has_database_id","subj":"1866","obj":"MESH:D017382"},{"id":"A1867","pred":"tao:has_database_id","subj":"1867","obj":"MESH:C026285"},{"id":"A1868","pred":"tao:has_database_id","subj":"1868","obj":"MESH:D014280"},{"id":"A1869","pred":"tao:has_database_id","subj":"1869","obj":"MESH:D013931"},{"id":"A1873","pred":"tao:has_database_id","subj":"1873","obj":"MESH:D001778"},{"id":"A1874","pred":"tao:has_database_id","subj":"1874","obj":"MESH:D007249"},{"id":"A1875","pred":"tao:has_database_id","subj":"1875","obj":"MESH:C000657245"},{"id":"A1907","pred":"tao:has_database_id","subj":"1907","obj":"MESH:D015525"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"inflammatory and the cardioprotective ACE2/Ang (1–7) effectors. (E) N-3 PUFAs enhance antioxidant capacity and attenuate oxidative stress in the tissue. (F) N-3 PUFAs ameliorate coagulopathy by exerting anti-thrombotic effects. (G) The triglyceride-lowering effect of n-3 PUFAs may play a key role in blunting the exaggerated inflammation observed in patients with COVID-19. ACE, Angiotensin-converting enzyme; Ang, Angiotensin; CRP, C-reactive protein; IL, Interleukin; mtDNA, Mitochondrial DNA; PUFA, Poly unsaturated fatty acid; ROS, Reactive oxygen species; TGs, Triglycerides; TNF-α, Tumor necrosis factor alpha; TX, Thromboxane.\n\n8.1 The anti-inflammatory properties of n-3 PUFAs\nAs me"}